Back in March, Roche revealed that its breast cancer pill had failed in a pivotal Phase 3 trial. Data presented at ASCO reveal why.
June 2, 2026 08:00 AM EDT
Roche details narrow failure of breast cancer pill trial
Elizabeth Cairns
Senior biopharma journalist
Back in March, Roche revealed that the breast cancer pill on which it had pinned billion-dollar sales expectations had failed in a …
Cancer breakthrough as new 'game-changing' pill could double survival time
'Wonder pill' can shrink tumours across six major cancers, trial shows
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
Biotech Plummets On Cancer Disappointment. What Happened?
ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win
ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker
A turning point for pancreatic cancer patients
ASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it?
Pfizer and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals.
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
Zealand Pharma falls 32% following mid-stage trial results for treatment being developed with Roche
Europe's CHMP backed AstraZeneca's camizestrant for breast cancer, diverging from a recent FDA committee vote, as well as Novo…
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended…
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
